已收盤 10-17 16:00:00 美东时间
-0.210
-1.84%
Kiniksa Pharmaceuticals announced that the FDA granted Orphan Drug Designation to KPL-387 for treating pericarditis. KPL-387, a monoclonal antibody, inhibits IL-1α and IL-1β signaling. The company expects Phase 2/3 trial data in late 2026 and believes KPL-387 could offer a monthly subcutaneous self-injection treatment option. Orphan Drug Designation provides incentives for developing treatments for rare diseases.
10-17 12:00
On September 29, 2025, Katapult Holdings, Inc. (the "Company") entered into the Limited Waiver (the "Second Limited Waiver") to our Amended and Restated Loan and Security Agreement, dated as of June 12, 2025 (as amended,
09-30 05:15
On September 15, 2025, Katapult Holdings, Inc. (the "Company") entered into the Limited Waiver (the "Limited Waiver") to our Amended and Restated Loan and Security Agreement, dated as of June 12, 2025 (as amended,
09-16 20:21
Goldman Sachs investment strategists have identified three promising investment opportunities as we enter the final quarter of 2025: alternative asset managers, companies with high floating rate debt,...
09-09 03:15
3 software stocks, Intrusion, Katapult, & PaySign, surge in momentum rankings, signaling strong price performance in the sector.
09-04 20:42
Katapult Holdings, Inc. announced that its CEO, Orlando Zayas, and CFO, Nancy Walsh, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025. Orlando Zayas will present an overview of Katapult's business. The presentation will be available on-demand starting September 5, 2025, at 7:00 AM ET via Katapult's Investor Relations website. Institutional investors can register for the conference to ac...
09-02 20:02
Stephens & Co. analyst Kyle Joseph maintains Katapult Holdings (NASDAQ:KPLT) with a Equal-Weight and raises the price target from $9 to $10.
08-14 21:56
Katapult Holdings (NASDAQ:KPLT) FY2025 Revenue expected to be more than $296.633M vs $296.300M Est
08-13 18:07
Katapult Holdings (NASDAQ:KPLT) sees Q3 sales of $72.368 million-$75.384 million vs $74.750 million analyst estimate.
08-13 18:06